Key result
The TAFI 505G allele was associated with a mildly increased risk of deep venous thrombosis (OR 1.3) despite being associated with lower TAFI antigen levels.
Why the study?
Do genetic variants in the TAFI gene affect the risk of deep venous thrombosis?
Case-Control (n=943)
Do genetic variants in the TAFI gene affect the risk of deep venous thrombosis?
Carriers of the TAFI 505G allele have an increased risk of DVT despite having lower TAFI antigen levels, indicating a complex relationship between TAFI and venous thrombosis.
Mild DVT risk link with TAFI 505G despite lower antigen levels is hypothesis-generating; leaves causal role and clinical utility open.
Thrombin activatable fibrinolysis inhibitor (TAFI) is an important inhibitor of fibrinolysis. High TAFI antigen levels are associated with an increased risk of deep venous thrombosis (DVT). Because TAFI levels are partly determined genetically, we assessed the association between three TAFI gene polymorphisms (-438 G/A, 505 A/G and 1040 C/T), TAFI antigen levels and clot lysis times and the risk of DVT. Carriers of the 505G allele, which is associated with lower TAFI antigen levels than the 505A allele, showed an increased risk of DVT. This indicates that the relationship between TAFI and venous thrombosis is more complex than previously suggested.
No takes yet. Share an insight, caveat, or question.
Martini et al. (2006) conducted a case-control in Deep venous thrombosis (n=943). TAFI 505G allele vs. Non-carriers or other TAFI haplotypes was evaluated on Risk of venous thrombosis (OR 1.3, 95% CI 1.0-1.6). The TAFI 505G allele was associated with a mildly increased risk of deep venous thrombosis (OR 1.3) despite being associated with lower TAFI antigen levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: